Clinical Trial Update: A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and immunogenicity of the Rlp2086 vaccine in two- or three-dose regimens in healthy adolescents aged 11 to under 1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• rLP2086 vaccine

Snippet

Sponsor: Pfizer | Conditions: Meningococcal Vaccine | Phase 2 | Status: COMPLETED | Results posted: 2015-06-04